MMB

DRUG2 trials

Sponsors

Sierra Oncology LLC - a GSK company, GlaxoSmithKline

Conditions

NeoplasmsPost-essential Thrombocythemia Myelofibrosis (Post-ET MF)Post-polycythemia Vera (Post-PV) MyelofibrosisPost-polycythemia Vera Myelofibrosis (Post-PV MF)Postessential Thrombocythemia (Post-ET) MyelofibrosisPrimary MyelofibrosisPrimary Myelofibrosis (PMF)

Phase 2

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

CompletedNCT02515630

Sierra Oncology LLC - a GSK companyPostessential Thrombocythemia (Post-ET) Myelofibrosis, Post-polycythemia Vera (Post-PV) Myelofibrosis, Primary Myelofibrosis (PMF)

Start: 2016-01-29End: 2017-08-15Updated: 2023-06-18

Extended Access of Momelotinib in Adults With Myelofibrosis

Active, not recruitingNCT03441113

GlaxoSmithKlineNeoplasms, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF) +2

Start: 2018-05-03End: 2026-12-11Updated: 2026-06-18

Related Papers

Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.

2024-10-167 citations

Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.

Journal of Clinical Oncology2024-06-01

Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

eJHaem2024-02-0117 citations

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.

2023-07-2725 citations

Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials

Blood Advances2023-07-1444 citations

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Blood Advances2020-09-11119 citations